Ocugen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
MALVERN, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21 at 1:40 p.m.
Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present virtually to provide an update on the development of Ocugen’s breakthrough modifier gene therapy platform as well as its novel biologic product candidate. He will highlight Ocugen’s lead product candidate, OCU400, which has the potential to treat many forms of retinitis pigmentosa and just received its fourth FDA orphan drug designation. Dr. Musunuri will share Ocugen’s recent accomplishments and its upcoming planned near and medium-term milestones.
Conference: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
The Oppenheimer Fall Healthcare Life Sciences & MedTech Summit will take place virtually on September 21-23.
About Ocugen, Inc.
Cautionary Note on Forward-Looking Statements
An Edge-to-Edge Smart Building Solution
Session Details TBA
Exhibitor Setup - Hall D